Patents by Inventor Ning F. Go

Ning F. Go has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Telomere length measurement in formalin-fixed, paraffin embedded (FFPE) samples by quantitative PCR
    Patent number: 9624542
    Abstract: Methods of reliably quantifying telomere length in cells or tissues that have been formalin fixed and paraffin embedded (FFPE) samples by quantitative polymerase chain reaction protocol and kits for use with such various methods are provided. The methods of the present invention may be used to predetermine an individual's response to treatment with a telomerase inhibitor, a telomere damaging agent or a telomerase activator.
    Type: Grant
    Filed: March 26, 2012
    Date of Patent: April 18, 2017
    Assignee: Geron Corporation
    Inventors: Hui Wang, Ning F. Go, Zhu Zhen Pirot
  • Treatment of Carcinomas with a Combination of EGF-Pathway and Telomerase Inhibitors
    Publication number: 20150359883
    Abstract: A method and kit for inhibiting the proliferation of carcinoma cells are disclosed, based on a combination of an EGF pathway inhibitor and a telomerase inhibitor. When used in cancer therapy, the two compounds in combination enhance the anti-cancer treatment efficacy obtained with the antibody alone or the telomerase inhibitor alone.
    Type: Application
    Filed: August 31, 2015
    Publication date: December 17, 2015
    Inventors: Robert J. Tressler, Ning F. Go
  • Treatment of carcinomas with a combination of EGF-pathway and telomerase inhibitors
    Patent number: 9155753
    Abstract: A method and kit for inhibiting the proliferation of carcinoma cells are disclosed, based on a combination of an EGF pathway inhibitor and a telomerase inhibitor. When used in cancer therapy, the two compounds in combination enhance the anti-cancer treatment efficacy obtained with the antibody alone or the telomerase inhibitor alone.
    Type: Grant
    Filed: March 6, 2008
    Date of Patent: October 13, 2015
    Assignee: Geron Corporation
    Inventors: Robert J. Tressler, Ning F. Go
  • Telomere Length Measurement in Formalin-Fixed, Paraffin Embedded (FFPE) Samples by Quantitative PCR
    Publication number: 20140248622
    Abstract: Methods of reliably quantifying telomere length in cells or tissues that have been formalin fixed and paraffin embedded (FFPE) samples by quantitative polymerase chain reaction protocol and kits for use with such various methods are provided. The methods of the present invention may be used to predetermine an individual's response to treatment with a telomerase inhibitor, a telomere damaging agent or a telomerase activator.
    Type: Application
    Filed: March 26, 2012
    Publication date: September 4, 2014
    Applicant: Geron Corporation
    Inventors: Hui Wang, Ning F. Go, Zhu Zhen Pirot
  • Combined telomerase inhibitor and gemcitabine for the treatment of cancer
    Patent number: 7989428
    Abstract: A method and kit for inhibiting the proliferation of cancer cells are disclosed, based on a combination of a gemcitabine and a telomerase inhibitor. When used in cancer therapy, the two compounds in combination enhance the anti-cancer treatment efficacy obtained with gemcitabine alone or the telomerase inhibitor alone. Preferably, efficacy is supraadditive or synergistic in nature relative to the combined effects of the individual agents, with minimal exacerbation of side effects.
    Type: Grant
    Filed: October 30, 2007
    Date of Patent: August 2, 2011
    Assignee: Geron Corporation
    Inventors: Ning F. Go, Robert J. Tressler
  • Treatment of Carcinomas with a Combination of EGF-Pathway and Telomerase Inhibitors
    Publication number: 20100104586
    Abstract: A method and kit for inhibiting the proliferation of carcinoma cells are disclosed, based on a combination of an EGF pathway inhibitor and a telomerase inhibitor. When used in cancer therapy, the two compounds in combination enhance the anti-cancer treatment efficacy obtained with the antibody alone or the telomerase inhibitor alone.
    Type: Application
    Filed: March 6, 2008
    Publication date: April 29, 2010
    Applicant: Geron Corporation
    Inventors: Robert J. Tressler, Ning F. Go
  • Combined Telomerase Inhibitor and Gemcitabine for the Treatment of Cancer
    Publication number: 20100016407
    Abstract: A method and kit for inhibiting the proliferation of cancer cells are disclosed, based on a combination of a gemcitabine and a telomerase inhibitor. When used in cancer therapy, the two compounds in combination enhance the anti-cancer treatment efficacy obtained with gemcitabine alone or the telomerase inhibitor alone. Preferably, efficacy is supraadditive or synergistic in nature relative to the combined effects of the individual agents, with minimal exacerbation of side effects.
    Type: Application
    Filed: October 30, 2007
    Publication date: January 21, 2010
    Applicant: Geron Corporation
    Inventors: Ning F. Go, Robert J. Tressler
  • Hair Follicle Pharmacodynamic Assay for Telomerase Activity
    Publication number: 20090142770
    Abstract: The invention is directed to methods for determining the efficacy of treatment with telomerase modulators in mammals by the analysis of the level of telomerase reverse transcriptase activity in mammalian hair follicle cells.
    Type: Application
    Filed: December 3, 2008
    Publication date: June 4, 2009
    Applicant: Geron Corporation
    Inventors: Ning F. Go, Calvin B. Harley, Ekaterina Bassett, Zhu Zhen Pirot